WO1992013563A1 - Preparation antitumorale et son procede de production - Google Patents
Preparation antitumorale et son procede de production Download PDFInfo
- Publication number
- WO1992013563A1 WO1992013563A1 PCT/RO1992/000024 RO9200024W WO9213563A1 WO 1992013563 A1 WO1992013563 A1 WO 1992013563A1 RO 9200024 W RO9200024 W RO 9200024W WO 9213563 A1 WO9213563 A1 WO 9213563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- treatment
- preparation
- product
- radiation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229910052742 iron Inorganic materials 0.000 claims abstract description 21
- 230000002285 radioactive effect Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 230000004907 flux Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 44
- 206010027476 Metastases Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 8
- 229910021653 sulphate ion Inorganic materials 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 231100000748 severe hepatic injury Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the area of technology 5 The missing invention is in the field of medicine, and more precisely, of a new device for the treatment and use of it.
- the 90 gamma odonuclide is used to treat cataracts up to 3 cm, which are localized in both a simple and convenient cortex.
- the indicated preparation is delivered, dose 30 m. 3 2 ⁇ Find a name for the treatment of malignant
- Radiopharmaceuticals ⁇ Necessary chemical products. All of the aforementioned shortcomings and technical complications of the radiotherapy of pharmaceutical products do not impair the implementation of the system.
- the literature has accumulated material on the possibility of using iron preparations, including radionuclide 59 -? E, for diagnosis in oncology. It is known, for example, a method of research of an erythropoiesis, diagnosis of anemia with the aid of a radioactive
- nucleus 59th 15 nucleus 59th. It is a beta, hammock-emitter with a transition period of 45.1 days.
- a radioactive nuclide in the form of iron chloride is introduced into the circle. Immediately after the disappearance of the radionuclide from plasma, there is an activity of an eritrogenic tissue. Indicated
- the 20th method allows the use of radionuclide 59, which is only for diagnostic purposes. goals.
- the use of a radioactive nuclide for medicinal purposes is not known.
- any type of pharmaceutical compound used for example, a non-ferrous substance, is a non-ferrous substance.
- the inventive product shows the impact on and on the main cells circulating the short circuit and are potential sources of development of the metastasis.
- a wide area of application may be used for the treatment of various malignant diseases, including the disease. the mammary gland, the testes, the matrices, the pulmonary artery, the lymphoma and the other
- the product is manufactured by a simple technician, it is available
- nuclear processes may be used for different types. Iron or iron compounds. in quality terms
- the inventive preparation was tested in the clinic. 5 Treatment is indicated for 30 patients with various malignant diseases, including cancer of the mammary gland, ovaries, uterus, lung cancer, skin, lymphoma, and others.
- the treatment was carried out in an individual mode, taking into account the age and general condition of the patient.
- the treatment of the patient is 15 ples I I pills the drug 2 times a day for 15 days. The treatment was repeated after I, 3, and 6 months.
- the treatment with the claimed device may also be combined with the best treatment (before or after treatment).
- Example II The results, similar to those described in Example I, are obtained under conditions similar to Example I. Irradiation of 20 is carried out for 12 hours. Indicated Radiative Sustainability Table 59 -? E 0.6 mi. The resulting preparation can withstand 4 days for the decay of the available nuclides.
- radionuclide 59 ze, having an activity of ⁇ 5 -radiation of 0.6MI per one tablet (dose) of the drug. No comorbid radionuclides have been identified. It is suitable for connection.
- Example II Items similar to those specified in Example I are subject to conditions similar to those in I for 48 hours. Induced performance of a single sulphate tablet 59 i * e is 10 mi. The product is discharged for 5 days for the decay of the associated damage
- Sick ⁇ . , 66 years old, diagnosed with ovarian cancer ⁇ U is a clinical group.
- the operation could not be performed in the 15th form due to the distribution of the process.
- ⁇ The largest area is up to 30 cm in diameter, enlarged lymph nodes.
- We begin to treat the treatment by treating them as described in the first paragraph.
- the preparation was terminated on the first tablet 2 times a day for the first month. On the 2nd day of life, much 20 softened significantly.
- the treatment was completed after I and 3 months. After I, the year showed that the condition is more satisfactory.
- Deliberate use of the Applied Patient Treatments 25 uses for the treatment of various malignant diseases, malignant disease, ovarian disease,
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Préparation anti-tumorale constituée d'un nuclide radioactif 59Fe ou d'une composition le contenant, et présentant une radioactivité β-non inférieure à 0,5 mc par dose de la préparation. Un procédé de production de ladite préparation consiste à soumettre du fer ou un composé à base de fer au flux de neutrons jusqu'à ce que la radioactivité β dudit composé atteigne un niveau non inférieur à 0,5 mc, après quoi l'on conditionne la préparation jusqu'à désintégration des nuclides radioactifs associés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU4905853 | 1991-01-31 | ||
| SU914905853A RU1837891C (ru) | 1991-01-31 | 1991-01-31 | Способ получени противоопухолевого средства |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992013563A1 true WO1992013563A1 (fr) | 1992-08-20 |
Family
ID=21557490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RO1992/000024 WO1992013563A1 (fr) | 1991-01-31 | 1992-01-31 | Preparation antitumorale et son procede de production |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU1837891C (fr) |
| WO (1) | WO1992013563A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003042404A3 (fr) * | 2001-11-13 | 2003-12-31 | David A Sirbasku | Programme d'eradication du cancer du sein |
| US7863011B2 (en) | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
| US7947275B2 (en) | 2000-05-10 | 2011-05-24 | Signe Biopharma, Inc. | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| US8038999B2 (en) | 2000-05-10 | 2011-10-18 | Sirbasku David A | Breast cancer eradication program |
| US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4303636A (en) * | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
| US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| WO1991010452A1 (fr) * | 1990-01-22 | 1991-07-25 | Teleki Peter | Procede ameliore de preparation d'une composition d'oxyde de fer destinee au traitement therapeutique d'un corps vivant, et composition d'oxyde de fer |
-
1991
- 1991-01-31 RU SU914905853A patent/RU1837891C/ru active
-
1992
- 1992-01-31 WO PCT/RO1992/000024 patent/WO1992013563A1/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4303636A (en) * | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
| US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| WO1991010452A1 (fr) * | 1990-01-22 | 1991-07-25 | Teleki Peter | Procede ameliore de preparation d'une composition d'oxyde de fer destinee au traitement therapeutique d'un corps vivant, et composition d'oxyde de fer |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863011B2 (en) | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
| US7947275B2 (en) | 2000-05-10 | 2011-05-24 | Signe Biopharma, Inc. | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| US7947463B2 (en) | 2000-05-10 | 2011-05-24 | Signe Biopharma, Inc. | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| US8038999B2 (en) | 2000-05-10 | 2011-10-18 | Sirbasku David A | Breast cancer eradication program |
| US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
| US8563249B2 (en) | 2000-05-10 | 2013-10-22 | Signe Biopharma Inc. | Receptor gene screening for detecting or diagnosing cancer |
| WO2003042404A3 (fr) * | 2001-11-13 | 2003-12-31 | David A Sirbasku | Programme d'eradication du cancer du sein |
Also Published As
| Publication number | Publication date |
|---|---|
| RU1837891C (ru) | 1993-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| D'Angio et al. | Potentiation of x-ray effects by actinomycin D | |
| Cohen et al. | Medical management of radiation accidents | |
| Chan et al. | Management and results of localized Ewing's sarcoma | |
| Valeriote et al. | Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721 | |
| Van Scott et al. | Responses of mycosis fungoides to intensive external treatment with nitrogen mustard | |
| BEIERWALTES et al. | Hyperthyroidism Treated with Radioiodine: A Seven-Year Experience | |
| Nenot | Medical and surgical management for localized radiation injuries | |
| Dolphin | Biological hazards of radiation | |
| WO1992013563A1 (fr) | Preparation antitumorale et son procede de production | |
| Burnet et al. | Phosphorus-32 for intractable bony pain from carcinoma of the prostate | |
| Paoletti | Therapeutic strategy for central nervous system tumors: present status, criticism and potential | |
| RU2053776C1 (ru) | Способ лечения онкологического заболевания | |
| Lin et al. | Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis | |
| Hahn et al. | The therapeutic use of radioactive elements in malignancy | |
| Huh et al. | Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model | |
| Kenney et al. | Further experiences in the treatment of lymphosarcoma with radioactive phosphorus | |
| Wick et al. | History and current uses of 224Ra in ankylosing spondylitis and other diseases | |
| McKay et al. | Treatment of hepatic cavernous haemangioma with radiation therapy: case report and literature review | |
| Tsavaris et al. | Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil | |
| Winfield et al. | Evaluation of two regimens to immobilise the knee after injections of yttrium-90. | |
| King | Use of total-body radiation in the treatment of far-advanced malignancies | |
| RU2182022C1 (ru) | Способ лечения онкологических заболеваний щитовидной железы | |
| US3885030A (en) | Medicine comprising lysine by-products | |
| CN110559305B (zh) | 唾液酸在制备电离辐射致肠道或dna损伤防护药物中的应用 | |
| WO2002041923A1 (fr) | Preparation destinee au traitement d'une affection oncologique et procedes de fabrication et d'application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |